Search Results

New study shows contrails forming inside cirrus clouds may add significantly to aviation-driven warming. < Back Hidden Contrails in Clouds Could Be Worsening Aviation’s Climate Impact New study shows contrails forming inside cirrus clouds may add significantly to aviation-driven warming. New research published in Nature Communications reveals that aircraft contrails, already known to contribute significantly to global warming, may have an even greater climate impact than previously estimated. The study highlights that many contrails form not in clear skies, but within existing cirrus clouds, where their effects have largely gone undetected and unaccounted for in climate models. Contrails form when hot, humid aircraft exhaust mixes with cold air at cruising altitudes, producing ice crystals that can spread into contrail cirrus. These high-altitude clouds trap outgoing heat and warm the planet, with an overall climate impact comparable to aviation’s carbon dioxide emissions. Until now, most assessments assumed contrails form mainly in clear skies, overlooking those embedded within natural cirrus clouds. Two complementary studies led by Petzold et al. and Seelig et al. challenge this assumption. Drawing on seven years of in-situ aircraft measurements, satellite observations, and meteorological data, the researchers show that contrail-favourable conditions frequently occur inside existing cirrus. In northern mid-latitudes, around half of these conditions arise within subvisible cirrus or near-clear skies, situations most likely to amplify warming, while the remainder occur within thicker cirrus clouds, where their climate effect is more complex. Using high-resolution lidar data from the CALIPSO satellite, Seelig et al. were able to isolate and quantify the radiative forcing of more than 40,000 embedded contrails. Their analysis found that these “hidden” contrails exert a measurable warming effect, particularly at night, and could add roughly 10% to current estimates of contrail-related radiative forcing when scaled globally. The findings suggest that embedded contrails represent a non-negligible and previously underestimated component of aviation’s overall climate footprint. They also underscore the challenge of distinguishing contrail-induced cirrus from natural clouds, a task that requires advanced satellite observations, aircraft trajectory data, and targeted atmospheric measurements. As global temperatures continue to rise, the research reinforces the urgency of addressing aviation’s non-CO₂ climate effects. Improved contrail detection and prediction, operational strategies such as altitude adjustments to avoid contrail-prone regions, and integration of natural cloud effects into climate models could offer near-term, cost-effective pathways to reduce aviation-related warming while longer-term solutions, including sustainable aviation fuels, continue to develop. Author BioFocus Newsroom Previous Next

BaseFold is pushing the boundaries of drug discovery by using AI and diverse biological data to predict complex protein structures with unprecedented accuracy. < Back BaseFold: Folding Proteins, Unfolding Possibilities BaseFold is pushing the boundaries of drug discovery by using AI and diverse biological data to predict complex protein structures with unprecedented accuracy. Artificial intelligence (AI) has become a transformative force in healthcare and biotechnology, particularly in drug discovery and molecular biology. Among its most critical applications is the prediction of protein structures, a long-standing challenge for researchers. Understanding a protein’s three-dimensional (3D) structure is fundamental for drug development, as it allows scientists to identify how proteins interact with potential drug molecules. Until recently, predicting these structures was a time-consuming, resource-intensive process, relying on experimental techniques like X-ray crystallography . AI, however, has revolutionized this field. DeepMind’s AlphaFold2 marked a major breakthrough by predicting protein structures from amino acid sequences with remarkable accuracy. Yet, despite its success, AlphaFold2 struggles with larger, more complex proteins , often underrepresented in public protein databases. This is where BaseFold, an AI-powered tool developed by Basecamp Research, steps in. Leveraging a more diverse dataset derived from global biodiversity, BaseFold has enhanced the accuracy of protein structure prediction, particularly for complex proteins, and is now an invaluable tool in AI-driven drug discovery. What Is Protein Structure Prediction? Protein structure prediction involves determining a protein’s 3D structure based on its amino acid sequence. This process is critical because a protein’s structure dictates its function and interaction with other molecules, which is essential for biological processes and drug discovery efforts. Proteins must fold into specific shapes to perform functions such as catalyzing reactions or binding to other molecules. Accurate models of these structures enable scientists to better understand these functions and inform drug design. Historically, predicting protein structures was challenging, requiring time-consuming methods like X-ray crystallography or nuclear magnetic resonance (NMR). Computational models struggled with accuracy, particularly for complex proteins, as early efforts depended on known templates. However, with AI’s rise, models like AlphaFold2 have drastically improved predictive capabilities , making accurate structure prediction faster and more accessible. Building on this foundation, BaseFold offers new possibilities by utilizing a broader array of biological data. AI’s Role in Protein Structure Prediction AI’s ability to predict 3D protein structures has fundamentally changed molecular biology. Traditionally, methods like X-ray crystallography were slow and expensive. However, AI has enabled rapid, cost-effective predictions. DeepMind’s AlphaFold2 transformed this space, offering predictions with near-experimental accuracy. AlphaFold2 leverages deep learning to analyze evolutionary relationships between proteins and predicts folding patterns using multiple sequence alignments (MSAs). Despite these advancements, AlphaFold2 encounters limitations with larger, complex proteins, which are underrepresented in common datasets. Here, BaseFold offers a critical advantage by expanding AI’s capabilities, predicting these complex structures more accurately and broadening drug discovery applications. BaseFold: The Next Frontier in AI-Driven Drug Discovery While AlphaFold2 set a new standard for protein structure prediction, BaseFold, developed by Basecamp Research , pushes these advancements further. BaseFold incorporates metagenomic DNA from diverse ecosystems, enriching its training models with a broader array of biological data. This innovation enables BaseFold to predict more complex protein structures with high accuracy—an essential step in developing new drug treatments. By utilizing data from extreme environments, BaseFold has access to unique protein sequences not found in traditional databases. This comprehensive dataset is particularly valuable for understanding proteins in unconventional or extreme conditions, offering insights critical to drug discovery. Furthermore, BaseFold excels in predicting small molecule interactions , a key aspect of early drug development. Why BaseFold Is a Game-Changer BaseFold’s advanced features suggest that it could significantly impact drug discovery. Its innovations present the opportunity for a broad range of future applications: A Diverse Dataset : By utilizing a more expansive dataset from biodiversity-rich ecosystems, BaseFold has the potential to predict the structures of larger, more complex proteins. These proteins, often involved in diseases like cancer or neurodegenerative disorders, are challenging to target using existing tools. BaseFold’s approach could open new avenues for therapeutic exploration. Enhanced Accuracy : With its demonstrated improvement in predicting complex protein structures, BaseFold holds promise for aiding in drug development. This level of accuracy could play a key role in streamlining the discovery process by reducing the need for extensive experimental validation. Improved Small Molecule Docking : BaseFold’s ability to enhance small molecule interaction predictions suggests its potential in early-stage drug discovery. The more reliable modeling of drug-protein interactions could make it a valuable tool for identifying effective therapeutic compounds, especially for proteins previously deemed difficult to target. Applications in Drug Discovery BaseFold’s enhanced predictive capabilities open possibilities for its use in drug discovery: Targeting Complex Proteins : BaseFold’s precise predictions of complex protein structures may help researchers identify new therapeutic opportunities for conditions like cystic fibrosis or cancer, where understanding protein folding is crucial. This could lead to the development of compounds that more effectively correct folding defects or inhibit disease-causing proteins. Antimicrobial Drug Discovery : As the need for new antibiotics grows due to rising antibiotic resistance , BaseFold’s ability to predict unusual protein structures could be instrumental in guiding the development of novel treatments. Its enhanced structural accuracy may allow researchers to target bacterial proteins that have evolved resistance mechanisms. BaseFold’s Future in AI and Biotech In the realm of personalized medicine , BaseFold’s accurate structure predictions could significantly improve the development of therapies tailored to individual patients. By providing detailed insights into how proteins interact with drugs at a molecular level, BaseFold has the potential to contribute to the creation of treatments designed around specific genetic profiles, leading to more effective, personalized outcomes. Additionally, treatments for rare diseases could benefit from BaseFold’s extensive dataset, which includes protein sequences from diverse and extreme ecosystems. The ability to predict the structure of rare, misfolded proteins might lead to the discovery of new therapeutic targets for conditions that currently lack effective treatments. The Power of Collaboration and Continuous Improvement The future success of BaseFold will depend on continuous collaboration and data integration. By partnering with organizations like NVIDIA and incorporating new data from diverse ecosystems, BaseFold will continue refining its AI models to achieve even higher accuracy. This collaborative approach will further enhance its utility in fields like cancer research, neurodegenerative diseases, and autoimmune disorders. Concluding Thoughts BaseFold represents a paradigm shift in protein structure prediction and drug discovery. By leveraging global biodiversity and enhancing predictive accuracy, BaseFold is transforming the way we approach complex diseases. Its integration into AI-driven platforms like NVIDIA BioNeMo underscores its importance in the future of biotechnology. Looking ahead, the fusion of AI and biotechnology, embodied by innovations like BaseFold, will shape the next generation of drug discovery. With the potential to accelerate treatments for complex diseases and improve personalized medicine, BaseFold is poised to become a cornerstone of modern medical research. Author Ramya Nadig , freelance contributor Previous Next

The recent collaboration between Lonza’s Synaffix and BigHat Biosciences exemplifies the growing convergence of biotechnology with machine learning to produce next-generation cancer therapies. < Back Advancing the Future of ADCs through Machine Learning: Lonza’s Synaffix and BigHat Biosciences Collaboration The recent collaboration between Lonza’s Synaffix and BigHat Biosciences exemplifies the growing convergence of biotechnology with machine learning to produce next-generation cancer therapies. Antibody-drug conjugates (ADCs) are at the forefront of oncology treatment, offering a targeted therapeutic approach that delivers potent drugs directly to cancer cells, thereby minimizing systemic toxicity. This partnership combines BigHat’s ML (machine learning)-based antibody design platform, Milliner™ , with Synaffix’s proprietary ADC technology to develop a highly differentiated, effective, and safe ADC pipeline. Synaffix and BigHat Biosciences: Pioneers in ADC Innovation ADCs are designed to selectively deliver cytotoxic agents to cancer cells by harnessing the specificity of antibodies. However, achieving both selectivity and efficacy remains a challenge due to the inherent complexity of the antibody-drug conjugate structure. This is where Synaffix’s ADC technology platform becomes instrumental. Comprised of GlycoConnect™ , HydraSpace® , and toxSYN® technologies, the Synaffix platform provides a comprehensive toolkit that optimizes ADC drug-like properties and enhances efficacy and tolerability. Lonza's acquisition of Synaffix in June 2023 further strengthens this offering, creating an integrated, end-to-end service that accelerates the path from DNA to Investigational New Drug (IND) application. Synaffix's GlycoConnect™ technology provides site-specific payload attachment, utilizing antibody glycan structures to increase stability. This approach, alongside HydraSpace®, which includes a polar spacer to enhance therapeutic index, and toxSYN®, which features a suite of potent cytotoxic agents, positions Synaffix as a leading player in ADC development. These technologies collectively aim to maximize therapeutic index—a crucial parameter in ADC efficacy, denoting the balance between therapeutic effect and side effect profile.\ The Role of Machine Learning in ADC Development BigHat Biosciences brings a powerful AI/ML-driven platform, Milliner™ , to this collaboration, with the potential to redefine ADC design and production speed. Traditional antibody engineering processes can be time-consuming and resource-intensive, requiring extensive laboratory work to develop antibodies with optimal biophysical properties. Milliner™ accelerates this process by integrating synthetic biology with advanced ML models, allowing rapid iteration and optimization of antibody candidates. This platform streamlines antibody design, enabling the development of antibodies with complex functions tailored to withstand the demands of drug conjugation without compromising therapeutic efficacy. Through this collaboration, Synaffix’s GlycoConnect™ technology benefits from BigHat’s precisely engineered antibodies, optimized for stable payload attachment and high binding affinity to target antigens. This union of ML and ADC technology not only facilitates the rapid progression of BigHat’s ADCs but also enhances their therapeutic potential by creating more robust, stable, and effective antibody-drug conjugates. Toward a Fully Integrated ADC Development Pathway The collaboration enables BigHat to leverage Lonza's full suite of ADC services, from antibody production to clinical trial supply. This integration allows BigHat to develop ADC candidates efficiently, reducing the timelines traditionally required for IND-enabling studies. The pathway, facilitated by Lonza’s state-of-the-art facilities, includes bioconjugation, drug product filling, and clinical batch production, all under a single quality system. This seamless, vertically integrated approach underscores Lonza’s commitment to accelerating ADC pipelines and helping biotech partners bring transformative therapies to market more swiftly. The demand for ADCs in the oncology sector continues to rise, spurred by the pressing need for safer, targeted treatments. However, manufacturing and development bottlenecks remain, as the complexity of ADCs requires specialized knowledge and infrastructure at every step of production. The integration offered by Lonza through Synaffix’s platform is a significant advantage, providing companies like BigHat with a streamlined path from initial design to clinical readiness. With Lonza’s recent facility expansion to handle high-potency vial filling, the infrastructure is in place to meet increasing market demands while maintaining the highest quality standards. Potential Impact of the Collaboration on ADC Therapeutics This partnership between Synaffix and BigHat Biosciences has implications far beyond individual drug candidates, potentially influencing the future of ADCs across the oncology landscape. By combining Synaffix’s established technology with BigHat’s AI-driven antibody discovery, the collaboration can produce ADCs that deliver drugs more precisely to tumor cells, thus enhancing both safety and efficacy. This approach directly addresses the unmet medical needs in difficult-to-treat cancers, where traditional therapies often fail due to limited selectivity and high toxicity. With Milliner™ , BigHat can continuously refine and optimize antibodies, leveraging ML to minimize the attrition rate of ADC candidates during preclinical and clinical stages. As ADCs are notoriously challenging to develop, with only a limited number of approved ADCs on the market, such advances in antibody design can lead to higher success rates, faster development timelines, and more accessible treatments for patients. Conclusion The collaboration between Lonza’s Synaffix and BigHat Biosciences is a notable advancement in the ADC field, showcasing how the synergy of machine learning and cutting-edge bioconjugation technology can propel next-generation oncology therapies. Synaffix’s platform offers a streamlined solution for developing ADCs with high stability, selectivity, and safety, while BigHat’s ML-powered Milliner™ platform provides a faster, more effective pathway to antibody design and optimization. This partnership not only strengthens each company’s competitive edge but also highlights the transformative potential of integrating biotechnology with artificial intelligence in cancer treatment innovation. As ADC technology continues to evolve, collaborations such as this set the stage for a future where AI-enhanced biologics bring safer, more effective therapies to patients worldwide. Author BioFocus Newsroom Previous Next

Strategic partnerships in immuno-cncology propel Innovation, highlighting ProBio’s role in the $3.3 billion LM-299 cancer therapy breakthrough. < Back GenScript’s ProBio Pioneers Exciting Innovation in Immuno-Oncology Strategic partnerships in immuno-cncology propel Innovation, highlighting ProBio’s role in the $3.3 billion LM-299 cancer therapy breakthrough. The announcement that ProBio, a subsidiary of GenScript Biotech, has successfully licensed its PD-1 new molecular entity (NME) to LaNova Medicines marks a significant milestone in the biotech industry's ongoing battle against cancer. This collaboration, bolstered by LaNova’s subsequent $3.3 billion agreement with Merck & Co. for the development of the PD-1/VEGF bispecific antibody (LM-299 program), exemplifies the transformative power of strategic partnerships and innovation in immuno-oncology. The Role of PD-1 in Cancer Therapy The licensed PD-1 molecule developed by ProBio represents a cornerstone in next-generation cancer treatments. Programmed death-1 (PD-1) inhibitors are integral in immunotherapy, empowering the immune system to recognize and combat cancer cells. By pairing PD-1 with vascular endothelial growth factor (VEGF) inhibition in a bispecific antibody, LaNova aims to create a dual-action therapy capable of modulating the tumor microenvironment while directly enhancing immune response. This approach aligns with the broader industry trend of advancing combination therapies to tackle complex cancers more effectively. ProBio’s Business Model: A Competitive Edge ProBio’s integrated Contract Development and Manufacturing Organization (CDMO) model sets it apart from competitors. By combining the development of proprietary NMEs with collaborative process development and manufacturing, ProBio positions itself as a partner of choice for biotech companies aiming to bring novel therapies to market. The success of this partnership with LaNova not only reinforces ProBio’s commitment to cutting-edge research but also showcases its ability to execute high-value deals, such as the Merck-LaNova agreement. The financial implications of this partnership are significant. Beyond immediate revenue projections, the collaboration is poised to generate long-term value by demonstrating the scalability and market potential of ProBio’s innovative molecules. This reinforces its leadership in the immuno-oncology CDMO space. Strategic Growth for GenScript and ProBio The financial boost from the LaNova-Merck deal aligns with GenScript’s strategic plans to expand ProBio’s global manufacturing footprint, particularly at its Hopewell, NJ site. Such expansions are crucial for meeting the rising demand for advanced biologics and ensuring the company remains competitive in a fast-evolving landscape. GenScript’s diversified business model, encompassing life sciences, biologics manufacturing, and synthetic biology, provides a robust platform for sustained growth. The company’s reputation, supported by its extensive customer base and substantial contributions to scientific literature, underscores its ability to deliver high-quality products and services. Implications for the Biotech Industry This development exemplifies a broader trend in the biotech industry: the increasing reliance on collaborative ecosystems to drive innovation. Companies like ProBio and LaNova leverage complementary strengths, from early-stage molecule development to late-stage commercialization, accelerating time-to-market for potentially life-saving therapies. Moreover, the agreement underscores the growing interest in immuno-oncology as a therapeutic area with both high clinical impact and lucrative market potential. The PD-1/VEGF bispecific antibody highlights the shift toward multifunctional biologics, which hold the promise of addressing unmet medical needs in oncology. The licensing of ProBio’s PD-1 molecule and the subsequent deal between LaNova Medicines and Merck exemplify the biotech industry's ability to translate scientific innovation into meaningful therapeutic advances. By fostering collaborative partnerships and strategically expanding its capabilities, GenScript’s ProBio is not only advancing the fight against cancer but also redefining the role of CDMOs in the pharmaceutical value chain. This achievement is a testament to the power of innovation and partnership in shaping the future of healthcare. Author BioFocus Newsroom Previous Next

$8B acquisition brings late-stage bispecific antibody petosemtamab into Genmab’s pipeline, accelerating shift to a wholly owned model with potential blockbuster launches by 2027. < Back Genmab to Acquire Merus in $8B Deal, Adding Breakthrough Oncology Asset to Late-Stage Pipeline $8B acquisition brings late-stage bispecific antibody petosemtamab into Genmab’s pipeline, accelerating shift to a wholly owned model with potential blockbuster launches by 2027. Genmab A/S (Nasdaq: GMAB) has announced plans to acquire Merus N.V. (Nasdaq: MRUS) in an all-cash transaction valued at approximately $8.0 billion, marking a major step in Genmab’s evolution toward a fully owned, late-stage pipeline model. Under the agreement, Genmab will acquire all outstanding shares of Merus for $97.00 per share, a 41% premium over Merus’ September 26 closing price. The deal, unanimously approved by both companies’ boards, is expected to close in early Q1 2026 pending customary conditions, including a minimum 80% tender of shares. Strategic fit: strengthening Genmab’s late-stage pipeline The acquisition brings Merus’ petosemtamab, an EGFRxLGR5 bispecific antibody currently in Phase 3 trials for head and neck cancer, into Genmab’s portfolio. The asset has already received two Breakthrough Therapy Designations from the FDA and showed promising Phase 2 data at ASCO 2025, with both response rates and median progression-free survival outperforming standard of care. Genmab expects petosemtamab to launch as early as 2027, subject to trial outcomes and regulatory approvals, with blockbuster potential and a forecast of at least $1 billion in annual sales by 2029. The company also plans to expand development into earlier lines of therapy and additional indications. “This acquisition clearly aligns with our long-term strategy,” said Jan van de Winkel, Ph.D., President and CEO of Genmab. “Petosemtamab has the potential to be a transformational therapy for patients living with head and neck cancer. With our proven track record in clinical development and commercialization, we are confident we can unlock its promise while accelerating Genmab’s evolution into a global biotechnology leader.” Bill Lundberg, M.D., President and CEO of Merus, added: “Genmab has the right vision and experience to advance petosemtamab in recurrent and metastatic head and neck cancer and beyond. I’m proud of the Merus team for pioneering our Multiclonics® platform and advancing a product candidate with the potential to make a real difference for patients.” Financial details and outlook The acquisition will be funded through a mix of cash on hand and approximately $5.5 billion in non-convertible debt financing underwritten by Morgan Stanley. Genmab expects the transaction to be EBITDA accretive by 2029, while maintaining its target to deleverage to under 3x gross leverage within two years of closing. The transaction does not affect Genmab’s FY2025 guidance, with an updated 2026 outlook to be shared alongside year-end results in February 2026. Industry impact The deal underscores a broader industry trend of biopharma companies seeking to consolidate late-stage oncology assets with strong commercial potential. For Genmab, best known for its antibody expertise and collaborative business model, the acquisition of Merus signals a decisive pivot toward a wholly owned portfolio, with four proprietary programs on track to support multiple launches by 2027. Author BioFocus Newsroom Previous Next

AstraZeneca announces acquisition of EsoBiotec for $1 billion, aiming to advance its cell therapy capabilities with EsoBiotec's in vivo genetic programming platform for cancer and immune-mediated diseases. < Back AstraZeneca to Acquire EsoBiotec in $1B Deal to Drive Next-Generation Cell Therapy AstraZeneca announces acquisition of EsoBiotec for $1 billion, aiming to advance its cell therapy capabilities with EsoBiotec's in vivo genetic programming platform for cancer and immune-mediated diseases. AstraZeneca (LSE/STO/Nasdaq: AZN) has announced the acquisition of EsoBiotec, a leader in pioneering in vivo cell therapies. The acquisition centers around EsoBiotec’s innovative Engineered NanoBody Lentiviral (ENaBL) platform, which offers a transformative approach to cancer treatment and immune-mediated diseases. EsoBiotec's cutting-edge technology delivers genetic instructions directly to immune cells like T cells using targeted lentiviruses, enabling rapid, on-site programming without the need for cell removal and extended processing. This method can deliver cell therapies in a matter of minutes through a simple IV injection—reducing the complexities and timelines associated with traditional treatments that can take weeks. AstraZeneca’s Executive Vice President of Oncology Haematology R&D, Susan Galbraith, expressed her enthusiasm, stating, “We are excited to advance EsoBiotec’s promising in vivo platform, which has the potential to transform cell therapy and enable greater patient access globally.” The deal, valued at up to $1 billion, includes an initial payment of $425 million and additional contingent payments based on development and regulatory milestones. The acquisition will bolster AstraZeneca's cell therapy portfolio, aligning with the company’s mission to expand access to transformative therapies worldwide. With operations based in Belgium, EsoBiotec will operate as a wholly owned subsidiary of AstraZeneca. The acquisition is expected to close in the second quarter of 2025, pending regulatory approvals. Author BioFocus Newsroom Previous Next

What do Protein Evolution, Stella McCartney and Sustainability have in common? We explore how Protein Evolution is shaping a circular economy for plastics and fashion. < Back Protein Evolution: Revolutionizing Recycling with Biotechnology What do Protein Evolution, Stella McCartney and Sustainability have in common? We explore how Protein Evolution is shaping a circular economy for plastics and fashion. Protein Evolution is an innovative biotechnology company that is transforming the recycling industry with its breakthrough Biopure™ technology. The company’s mission is to reduce plastic waste and fossil fuel consumption by creating infinitely recyclable polyester materials. Protein Evolution’s process uses waste-derived precursors to replace petroleum-based ones, revolutionizing traditional recycling methods and offering a sustainable alternative to linear production cycles. Founded in 2021 by Connor Lynn and Jonathan Rothberg, Ph.D., Protein Evolution is committed to advancing circular economy solutions for industries heavily reliant on plastic materials. Its technology aims to create new materials that can be infinitely recycled, thus reducing the environmental impact of plastic production and waste. Innovative Partnerships and Impact Protein Evolution’s impact extends beyond just technological innovation—it has formed strategic collaborations with influential players in both the fashion and sustainability sectors. One notable partnership is with the iconic fashion brand Stella McCartney, where Protein Evolution’s technology has been employed to produce garments using 100% recycled fibers. Together, Protein Evolution and Stella McCartney crafted the world’s first garments from this novel material, introduced at The 2023 United Nations Climate Change Conference or Conference of the Parties of the UNFCCC, more commonly known as COP28. Protein Evolution is also supported by the SOS Fund , a $200 million investment fund, co-founded by Stella McCartney, that is designed to support and empower the next generation of innovators. This collaboration underscores the growing demand for sustainable practices in the fashion industry and highlights Protein Evolution’s role in shaping future material supply chains. The company’s commitment to sustainability is also evident in its partnerships with research institutions and other biotechnology innovators, including Basecamp Research. You can read more about the work Basecamp Research is doing in our article . These collaborations further propel the development of new recycling technologies and sustainable materials that are crucial for mitigating the ongoing plastic pollution crisis. Driving Change in Plastic and Textile Industries In addition to its work in fashion, Protein Evolution is positioning itself as a key player in the broader plastics industry. The company’s innovations have the potential to transform how industries across the globe approach waste management and material recycling. By making plastic production more sustainable, Protein Evolution is contributing to the reduction of carbon footprints and helping companies transition to a more sustainable business model. The company’s efforts go beyond just producing recyclable materials—they are working to create a new, more sustainable approach to plastic and textile production. Their technology is poised to be a game changer, offering new possibilities for closed-loop recycling systems across various sectors. Looking to the Future Protein Evolution’s journey is just beginning, but the impact of its technology is already significant. With a team of experts, a growing number of high-profile partnerships, and ongoing research, the company is paving the way for a future where plastics and textiles are no longer a source of pollution but an integral part of a sustainable, circular economy. As Protein Evolution continues to expand its reach and refine its technology, the company is set to play a leading role in the future of industrial biotechnology. With its mission to decarbonize plastic production and create infinitely recyclable materials, Protein Evolution is not just advancing a scientific innovation—it is shaping the future of sustainable materials on a global scale. For more information about Protein Evolution’s mission, technology, and partnerships, visit their website . Author BioFocus Newsroom Previous Next

IGM Biosciences is discontinuing its lead autoimmune programs, imvotamab and IGM-2644, following disappointing clinical results, and implementing a 73% workforce reduction while reevaluating its strategic direction. < Back IGM Biosciences Halts Lead Autoimmune Programs, Cuts Workforce by 73% IGM Biosciences is discontinuing its lead autoimmune programs, imvotamab and IGM-2644, following disappointing clinical results, and implementing a 73% workforce reduction while reevaluating its strategic direction. IGM Biosciences , a clinical-stage biotechnology company, has announced a major shift in its strategic direction, discontinuing its lead autoimmune programs and implementing significant workforce reductions. The company cited disappointing interim results from clinical studies as the primary reason behind its decision. Key Programs Discontinued The company’s lead program, imvotamab, a CD20 x CD3 bispecific IgM antibody, was being developed to treat rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Phase 1b trials revealed inconsistent and insufficient B cell depletion, a critical mechanism for the treatment of these autoimmune conditions. The company also discontinued its IGM-2644 program, a targeted effort to develop therapies for autoimmune and inflammatory diseases. Workforce and Financial Impact In response to these developments, IGM Biosciences announced a 73% workforce reduction, affecting approximately 144 employees. This restructuring is intended to conserve resources as the company re-evaluates its strategy. As of December 31, 2024, IGM reported $183.8 million in cash and investments, which will support the transition. Strategic Reevaluation Underway Dr. Mary Beth Harler, CEO of IGM Biosciences, expressed gratitude to the patients, investigators, and employees who contributed to the discontinued programs. She acknowledged the difficult but necessary decision to halt these projects and emphasized the company’s commitment to identifying new pathways to address unmet medical needs. IGM is now focused on assessing internal opportunities and exploring potential strategic alternatives to maximize shareholder value. Industry Implications The decision reflects the challenges of translating innovative therapeutic approaches into consistent clinical success. Analysts suggest that the company’s focus on IgM antibody technology, though promising, has struggled to deliver the required efficacy in autoimmune indications. Looking Forward While the discontinuation of these programs marks a setback, IGM’s proprietary IgM platform remains a potential asset for addressing other medical conditions. The company is expected to provide further updates as it refines its strategic priorities. This announcement follows a broader industry trend of biotech firms reassessing pipelines and conserving cash amid uncertain economic conditions and rising development costs. Author BioFocus Newsroom Previous Next

< Back World Health Summit 11th - 13th October, 2026 Berlin, Germany From Crisis to Resilience: Innovating for Health ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Previous Next

< Back World Health Summit 11th - 13th October, 2026 Berlin, Germany From Crisis to Resilience: Innovating for Health ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Previous Next

< Back World Health Summit 11th - 13th October, 2026 Berlin, Germany From Crisis to Resilience: Innovating for Health ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Previous Next

< Back World Health Summit 11th - 13th October, 2026 Berlin, Germany From Crisis to Resilience: Innovating for Health ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Previous Next